Dr. Timothy G. Larson, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of California, San Francisco School of Medicine (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 69
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: University of California, San Francisco School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MN license 38013
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Regions Hospital Saint PAul, MN
Medical groups
- Group Health Inc (1,638 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 69
- Services billed
- 3,316
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Injection, aprepitant, 1 mg | 6,240 | 25 |
| Injection, dexamethasone sodium phosphate, 1 mg | 1,080 | 38 |
| Injection, palonosetron hcl, 25 mcg | 670 | 30 |
| Injection, leucovorin calcium, per 50 mg | 540 | 11 |
| Injection, granisetron hydrochloride, 100 mcg | 500 | 18 |
| Injection, fluorouracil, 500 mg | 346 | 11 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 304 | 85 |
| Injection of additional new drug or substance into vein | 304 | 55 |
| Insertion of needle into vein for collection of blood sample | 225 | 80 |
| Blood test, comprehensive group of blood chemicals | 180 | 69 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Dexamethasone Other prescribers in Minneapolis, MN | 28 |
| Ondansetron Hcl Other prescribers in Minneapolis, MN | 23 |
| Lorazepam Other prescribers in Minneapolis, MN | 16 |
| Olanzapine Other prescribers in Minneapolis, MN | 16 |
| Tamoxifen Citrate Other prescribers in Minneapolis, MN | 15 |
| Eliquis (apixaban) Other prescribers in Minneapolis, MN | 14 |
| Imbruvica (ibrutinib) | 14 |
| Letrozole Other prescribers in Minneapolis, MN | 14 |
| Prochlorperazine Maleate Other prescribers in Minneapolis, MN | 14 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 5 payments worth $8,904 in total to this clinician.
| Genentech USA, Inc. | $8,661 |
|---|---|
| Genentech, Inc. | $164 |
| Tempus Ai, Inc | $79.10 |
| Consulting Fee | $8,025 |
|---|---|
| Travel and Lodging | $491 |
| Food and Beverage | $388 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech USA, Inc. Oct 22, 2025 | Consulting Fee | $8,025 |
| Genentech USA, Inc. Oct 22, 2025 | Travel and Lodging travel to St. Louis, MO · in-kind | $491 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $819,296 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309)
Amgen Inc. - A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo Inc. · Recruiting · NCT06172478 - A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Mas…
Amgen Inc. - A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer
AstraZeneca Pharmaceuticals LP - A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors
Amgen Inc. - An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
E.r. Squibb & Sons, L.l.c. · Completed · NCT02832167 - Single-arm, open label, phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investigator's choice (IV/SC/Oral) for patients with intermediate, high or very high risk myelodysplastic …
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.